XTNT
AMEXXtant Medical Holdings Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$0.46-0.17 (-27.62%)
2026-03-042026-06-05
News · 26 weeks24-89%
2025-12-142026-06-07
Mix1790d
- SEC Filings9(53%)
- Earnings4(24%)
- Other4(24%)
Latest news
25 items- SECSEC Form SD filed by Xtant Medical Holdings Inc.SD - Xtant Medical Holdings, Inc. (0001453593) (Filer)
- SECSEC Form S-8 POS filed by Xtant Medical Holdings Inc.S-8 POS - Xtant Medical Holdings, Inc. (0001453593) (Filer)
- SECSEC Form S-8 POS filed by Xtant Medical Holdings Inc.S-8 POS - Xtant Medical Holdings, Inc. (0001453593) (Filer)
- SECSEC Form S-8 POS filed by Xtant Medical Holdings Inc.S-8 POS - Xtant Medical Holdings, Inc. (0001453593) (Filer)
- SECSEC Form S-8 POS filed by Xtant Medical Holdings Inc.S-8 POS - Xtant Medical Holdings, Inc. (0001453593) (Filer)
- SECSEC Form 10-Q filed by Xtant Medical Holdings Inc.10-Q - Xtant Medical Holdings, Inc. (0001453593) (Filer)
- SECXtant Medical Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events8-K - Xtant Medical Holdings, Inc. (0001453593) (Filer)
- PRXtant Medical Reports First Quarter 2026 Financial ResultsRaises full-year 2026 revenue guidance to a range of $101-$105 millionSignificantly strengthens balance sheetEnters into exclusive U.S. distribution agreement for Dilon Technologies' HEMOBLAST® Bellows product for high-performance hemostasis; hires Dilon's U.S. sales teamBELGRADE, Mont., May 13, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today reported financial and operating results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Hi
- PRXtant Medical to Announce First Quarter 2026 Financial Results on May 13, 2026BELGRADE, Mont., May 7, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that it will release its financial results for the first quarter ended March 31, 2026, before the start of trading on Wednesday, May 13, 2026. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call at 8:30 AM ET on that day. Conference Details:Conference Date: Wednesday, May 13, 2026Conference Time: 8:30 AM ETC
- PRXtant Medical Expands Trivium™ Portfolio with the Commercial Launch of Trivium™ ShapedBELGRADE, Mont., May 6, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced the commercial launch of Trivium™ Shaped, an extension of its Trivium™ bone graft portfolio that is now available in pre‑shaped configurations designed to support handling, preparation, and placement across a range of surgical applications. Trivium Shaped builds on the success of the Trivium sculptable format (launched in April 2025) by offering surgeons ready-to-use graft fo
- SECXtant Medical Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Xtant Medical Holdings, Inc. (0001453593) (Filer)
- PRXtant Medical and Dilon Technologies Announce Exclusive U.S. Distribution Agreement for Dilon's HEMOBLAST® Bellows ProductXtant has hired Dilon's U.S. sales team to assist in selling the HEMOBLAST® Bellows product and penetrating the estimated $2.0 billion global addressable market for hemostatic products BELGRADE, Mont. and NEWPORT NEWS, Va., April 13, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, and Dilon Technologies, Inc., a medical device manufacturer, today announced that the companies have entered into an agreement whereby Xtant has acquired exclusive U.S. distribution rights to Dilon's HEMOBLAST® Bellows for high-performance hemostasis following certain surgical procedures.
- PRXtant Medical and Montana Governor's Office of Community Service Announce Support for "Threshold of Life" MemorialBELGRADE, Mont., April 9, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), in partnership with the Montana Governor's Office of Community Service (GOCS), today announced support for the Threshold of Life Memorial, a statewide initiative honoring organ, eye, and tissue donors and the lives they have impacted. Planned for installation on the Montana State Capitol grounds in Helena, the outdoor memorial will serve as a lasting tribute to donors, both living and deceased. It will be a place of reflection for families, recipients, and those awaiting transplantation. The
- SECSEC Form 10-K filed by Xtant Medical Holdings Inc.10-K - Xtant Medical Holdings, Inc. (0001453593) (Filer)
- SECXtant Medical Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Xtant Medical Holdings, Inc. (0001453593) (Filer)
- PRXtant Medical Reports Fourth Quarter and Full-Year 2025 Financial ResultsFull year 2025 revenue totals $133.9 million, an increase of 14% year-over-yearXtant delivers positive net income, adjusted EBITDA and operating cash flowTotal cash of $17.3 million as of December 31, 2025 with an additional $10.5 million received subsequent to year end related to divestitureBELGRADE, Mont., March 31, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today reported financial and operating results for the fourth quarter and full-year ended December 31, 2025.
- PRXtant Medical to Announce Fourth Quarter and Full Year 2025 Financial Results on March 31, 2026BELGRADE, Mont., March 25, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2025, before the start of trading on Tuesday, March 31, 2026. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call at 8:30 AM ET on that day. Conference Details:Conference Date: Tuesday, March 31, 2026Confere
- SECSEC Form 8-K filed by Xtant Medical Holdings Inc.8-K - Xtant Medical Holdings, Inc. (0001453593) (Filer)
- PRXtant Medical Finalizes Companion Spine TransactionsXtant received $10.7 million in satisfaction of unsecured promissory note issued to Xtant by Companion Spine plus related working capital adjustments BELGRADE, Mont., March 2, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that it has received $10.7 million from Companion Spine related to Companion Spine's purchase of Xtant's Coflex® assets and Paradigm OUS businesses in December 2025, bringing the total aggregate purchase price for the two divestitures to $21.4 million. With this payment, the transactions have now been finalized.
- PRXtant Medical to Participate in the Canaccord Genuity 2026 Musculoskeletal ConferenceBELGRADE, Mont., Feb. 25, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and wound care disorders, today announced that Sean Browne, CEO, Scott Neils, CFO, and Mark Schallenberger, COO, will be participating in the Canaccord Genuity 2026 Musculoskeletal Conference, which is being held March 2, 2026, in New Orleans and virtually. A webcast of the company's presentation will be available here as of Monday, February 2nd at 2:00 P.M. (ET). In addition, Xtant's m
- INSIDERChief Operating Officer Schallenberger Mark A. covered exercise/tax liability with 7,709 shares, decreasing direct ownership by 1% to 663,157 units (SEC Form 4)4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Xtant Medical Holdings Inc.SCHEDULE 13G/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)
- INSIDERCFO and Assistant Secretary Neils Scott C covered exercise/tax liability with 8,084 shares, decreasing direct ownership by 0.95% to 843,381 units (SEC Form 4)4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)
- SECSEC Form 8-K filed by Xtant Medical Holdings Inc.8-K - Xtant Medical Holdings, Inc. (0001453593) (Filer)
- PRXtant Medical Announces Commercial Launch of its Next-Generation nanOss Strata™ Synthetic Bone GraftnanOss Strata™ is designed to more closely mimic the structure of human bone, increase the graft's surface area, improve osteoconductivity and enhance the stimulation of cellular activity BELGRADE, Mont., Dec. 11, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced the commercial launch of its next-generation innovative synthetic bone graft in the nanOss line, Strata™. nanOss Strata is manufactured from hydroxycarbonapatite (HCA), a material with hi
XTNT FAQ
6 questionsWhat does Xtant Medical Holdings Inc. do?
Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis...Where does XTNT stock trade?
Xtant Medical Holdings Inc. (XTNT) is listed on AMEX.What sector and industry is XTNT in?
Xtant Medical Holdings Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about XTNT?
Xtant Medical Holdings Inc. has had 1 recent analyst action on file. The most recent action was from BTIG Research: Buy with a $200.00 price target on 2023-12-05. Recent price targets cluster around $200.00.What companies are similar to XTNT?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare XTNT side-by-side with any of them on Quantisnow.How can I track XTNT on Quantisnow?
Quantisnow aggregates Xtant Medical Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow XTNT to receive live email and push alerts on every new disclosure.